Clinical Trial Update: A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety, efficacy, and immunogenicity of the ChAd63-KH vaccine for cutaneous leishmaniasis (PKDL-related).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leishmaniasis Cutaneous

Drugs mentioned

• ChAd63-KH (ChAd63-KH)

Snippet

Sponsor: University of York | Conditions: Leishmaniasis, Cutaneous | Phase 2 | Status: COMPLETED